TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Two patients whose care faced insurance barriers obtained approval after contacting company executives, according to cases reported by MedPage Today. The examples suggest escalation can draw attention to individual claims, but they do not establish how often it succeeds or whether it is practical for most patients.
Two patients whose care had been denied or faced an out-of-network barrier received insurance approval after escalating their cases to senior company leaders, according to a MedPage Today report published October 8. The accounts show how direct appeals to executives may bring attention to individual disputes, but they do not establish how often the tactic works or whether it is accessible to patients without substantial time and help.
One patient, Elizabeth Nicholas, was diagnosed with breast cancer at age 36. After months of treatment, her insurer declined to cover the chemotherapy her oncologist recommended, MedPage Today reported. Nicholas emailed the insurer’s CEO and later received a message from its chief scientific officer saying the treatment had been approved. Her experience had also been described in a Vanity Fair article the previous month; the MedPage account says a journalist helped broker the resolution.
The second patient, Donald E. Grant Jr., 49, had severe congenital cervical stenosis. After an earlier two-level artificial disc replacement did not adequately decompress his spinal cord, he developed myelomalacia, the report said. Grant had surgery scheduled with Hyun Bae, a Cedars-Sinai spine surgeon, but Bae was out of network even though the other elements of the procedure were covered.
Grant used Claimable, an AI-assisted appeal platform, to prepare an 11-page submission setting out medical and legal arguments. It said his insurer lacked an in-network surgeon with comparable qualifications, cited relevant regulations, and asked that algorithms not be used to decide his case. Grant sent the appeal to UnitedHealth Group’s CEO and copied other company leaders, legislators and journalists. UnitedHealthcare approved the procedure at the in-network rate, according to the report.
Executive Appeals Can Change Individual Cases
The cases matter to patients facing time-sensitive care decisions because they illustrate a route beyond routine claims and appeals channels: bringing a dispute to executives who may oversee high-profile cases. Former insurance executive Wendell Potter, who highlighted the accounts in his Health Care Un-Covered newsletter, told MedPage Today that companies have staff who handle cases elevated to senior leadership or public relations. He said such cases receive special attention.
That does not show that executive emails routinely overturn denials. The report presents two successful examples, not a study of outcomes, and the cases involved extensive research, written advocacy and, in Nicholas’s case, journalistic involvement. Patients may have unequal ability to make that effort. The accounts also do not establish whether the approvals followed a formal reconsideration, an executive review, or another process inside the companies.
Potter said clinicians may be well placed to help because they understand the medical and insurance systems. But he warned that frequent escalation could carry professional risks. The broader implication is not that patients should have to reach executives to secure care, but that some disputes may attract attention only after ordinary channels fail.
AI-assisted insurance appeal platform
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Two Routes Around Routine Appeals
The cases differ in both the obstacle and how it was addressed. Nicholas challenged a refusal to cover the chemotherapy recommended by her oncologist. Grant sought coverage at the in-network rate for a surgeon who was outside his plan’s network, arguing that no comparable in-network specialist was available. In both accounts, the coverage outcome changed after senior-level escalation, but the specific review procedures used by the insurers are not detailed.
Potter said that, while working at Cigna, cases receiving media attention were elevated. He told MedPage Today that companies maintain teams around the CEO for high-profile matters and those referred to the C-suite or public relations staff. His comments offer a former executive’s description of company practice, not independent evidence about how all insurers handle escalated cases.
Potter also said many patients do not know how to contest a denial. Public Citizen healthcare policy advocate Eagan Kemp criticized the burden placed on patients and providers, telling MedPage Today it was absurd to require them to spend so much time securing approval for medically necessary care or tracking down company executives. Kemp said support for Medicare for All is growing partly because the model would remove middlemen.
“You can be certain that at big insurance companies, there is a group of people around the CEO who are dedicated to high-profile cases and cases that are elevated to the C-suite or to the PR department — and they get special attention.”
— Wendell Potter, former insurance company executive, speaking to MedPage Today
How Often Executive Appeals Work
The report does not provide data on how often emails to CEOs lead to coverage approval, how many similar appeals fail, or whether the two cases are representative. It also does not detail the insurers’ internal review steps, the reasons each decision changed, or whether the approvals created any precedent for other patients. Two accounts cannot establish a general success rate.
It remains unclear how patients can identify the right executive contact, what response times they might expect, or whether contacting leadership affects an active formal appeal. The report also does not establish whether using an AI-assisted tool changes appeal outcomes. Potter’s warning about possible consequences for clinicians is presented as a risk, not as a documented outcome in these cases.
Formal Appeals Remain Central
The report does not identify a new insurer policy or a scheduled regulatory action arising from the cases. For patients, the immediate question is how a company will review each individual dispute and what options remain if executive escalation does not resolve it. The available accounts describe successful outcomes, but provide no general guidance on deadlines, required documents or whether patients should pursue executive contact alongside formal appeal procedures.
Potter urged patients and clinicians not to treat an initial denial as the final word, while acknowledging that escalation should not be necessary to obtain appropriate care. Kemp’s criticism points to a wider policy debate about the time and administrative work involved in coverage decisions. Whether insurers change their processes, or whether these cases prompt further scrutiny, is not stated in the report.
Key Questions
What happened in the two cases?
Both patients obtained approval after their disputes reached senior company leaders. Elizabeth Nicholas received approval for the chemotherapy her oncologist recommended after emailing her insurer’s CEO. UnitedHealthcare approved Donald E. Grant Jr.’s surgery with an out-of-network surgeon at the in-network rate after he sent a detailed appeal to UnitedHealth Group’s CEO and copied other officials.
Does emailing an insurance CEO guarantee approval?
No. The report describes two successful cases but gives no success rate and does not show that the approach works for other patients. Results may depend on the facts of a claim, the evidence provided and the insurer’s review.
Did the patients use the same approach?
No. Nicholas emailed her insurer’s CEO after a chemotherapy coverage refusal; the report says a journalist helped broker the resolution. Grant prepared an 11-page medical and legal appeal with help from an AI-assisted platform and sent it to senior leaders, legislators and journalists.
What risks did the report mention?
Potter warned that frequent escalation by a doctor could annoy an insurer and potentially put the doctor’s network participation at risk. That was a warning about a possible risk, not a reported consequence in either patient’s case.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
